

## AMENDMENTS

2014—Subsec. (a)(1). Pub. L. 113-166, §2(1), substituted “Musculoskeletal” for “Muscoskeletal” and inserted “Becker, congenital muscular dystrophy, limb-girdle muscular dystrophy,” after “Duchenne.”

Subsec. (b)(2). Pub. L. 113-166, §2(2)(A), substituted “cardiac and pulmonary function, and pharmacological” for “genetics, pharmacological”.

Subsec. (b)(3). Pub. L. 113-166, §2(2)(B), inserted “and sharing of data” after “regular communication”.

Subsec. (d)(2). Pub. L. 113-166, §2(3)(A)(i), substituted “18” for “15” in introductory provisions.

Subsec. (d)(2)(A). Pub. L. 113-166, §2(3)(A)(ii), substituted “, the Food and Drug Administration, and the Administration for Community Living” for “and the Food and Drug Administration” and “including the Department of Education and the Social Security Administration” for “such as the Department of Education” and inserted “and adults” after “children”.

Subsec. (d)(4)(B). Pub. L. 113-166, §2(3)(B), inserted “, but shall meet no fewer than two times per calendar year” before period at end.

Subsec. (e)(1). Pub. L. 113-166, §2(4)(A)(i), substituted “through the agencies represented on the Coordinating Committee pursuant to subsection (d)(2)(A)” for “through the national research institutes” in introductory provisions.

Subsec. (e)(1)(A). Pub. L. 113-166, §2(4)(A)(ii), inserted “public services,” after “psychosocial,” and “, studies to demonstrate the cost-effectiveness of providing independent living resources and support to patients with various forms of muscular dystrophy, and studies to determine optimal clinical care interventions for adults with various forms of muscular dystrophy” after “including studies of the impact of such diseases in rural and underserved communities”.

Subsec. (e)(2)(D). Pub. L. 113-166, §2(4)(B), inserted “and new clinical interventions to improve the health of those with muscular dystrophy” after “including new biological agents”.

2008—Subsec. (a)(1). Pub. L. 110-361, §2(b)(1), inserted “the National Heart, Lung, and Blood Institute,” after “the Eunice Kennedy Shriver National Institute of Child Health and Human Development.”

Subsec. (b)(1). Pub. L. 110-361, §2(b)(2), inserted at end “Such centers of excellence shall be known as the ‘Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers.’”

Subsec. (f). Pub. L. 110-361, §2(a), redesignated subsec. (g) as (f) and struck out former subsec. (f) which related to reports.

Subsec. (g). Pub. L. 110-361, §2(a), (b)(3), added subsec. (g) and redesignated former subsec. (g) as (f).

2007—Pub. L. 109-482, §104(b)(1)(A)(ii), which directed amendment of subsec. (b) by striking subsec. (f) and redesignating subsec. (g) as (f), could not literally be executed and was not executed in view of amendments by Pub. L. 110-361. See 2008 Amendment notes above.

Subsec. (a)(1). Pub. L. 110-154 substituted “Eunice Kennedy Shriver National Institute of Child Health and Human Development” for “National Institute of Child Health and Human Development”.

Subsec. (b)(3). Pub. L. 109-482, §104(b)(1)(A)(i), amended heading and text of par. (3) generally. Text read as follows: “The Director of NIH—

“(A) shall, as appropriate, provide for the coordination of information among centers under paragraph (1) and ensure regular communication between such centers; and

“(B) shall require the periodic preparation of reports on the activities of the centers and the submission of the reports to the Director.”

Subsec. (h). Pub. L. 109-482, §103(b)(4), struck out heading and text of subsec. (h). Text read as follows: “For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2002 through 2006. The authorization of appropriations established in the preceding sentence is in addition to any other authoriza-

tion of appropriations that is available for conducting or supporting through the National Institutes of Health research and other activities with respect to muscular dystrophy.”

## EFFECTIVE DATE OF 2007 AMENDMENT

Amendment by Pub. L. 109-482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109-482, set out as a note under section 281 of this title.

**§§ 283h, 283i. Transferred**

## CODIFICATION

Section 283h, act July 1, 1944, ch. 373, title IV, §404F, as added Pub. L. 107-280, §3, Nov. 6, 2002, 116 Stat. 1989; amended Pub. L. 109-482, title I, §§103(b)(5), 104(b)(1)(B), Jan. 15, 2007, 120 Stat. 3687, 3693, which related to the Office of Rare Diseases, was renumbered section 481 of act July 1, 1944, by Pub. L. 112-74, div. F, title II, §221(c)(2)(A)(i), Dec. 23, 2011, 125 Stat. 1089, and transferred to section 287a-1 of this title.

Section 283i, act July 1, 1944, ch. 373, title IV, §404G, as added Pub. L. 107-280, §4, Nov. 6, 2002, 116 Stat. 1990; amended Pub. L. 109-482, title I, §103(b)(6), Jan. 15, 2007, 120 Stat. 3687, which related to rare disease regional centers of excellence, was renumbered section 481A of act July 1, 1944, by Pub. L. 112-74, div. F, title II, §221(c)(3), Dec. 23, 2011, 125 Stat. 1089, and transferred to section 287a-2 of this title.

**§ 283j. Repealed. Pub. L. 114-255, div. A, title II, § 2042(f)(1), Dec. 13, 2016, 130 Stat. 1073**

Section, July 1, 1944, ch. 373, title IV, §404H, as added Pub. L. 109-416, §2(b), Dec. 19, 2006, 120 Stat. 2821, required review and report on centers of excellence funded under this subchapter.

**§ 283k. Biomedical and behavioral research facilities****(a) Modernization and construction of facilities****(1) In general**

The Director of NIH, acting through the Office of the Director of NIH or the Director of the National Institute of Allergy and Infectious Diseases, may make grants or contracts to public and nonprofit private entities to expand, remodel, renovate, or alter existing research facilities or construct new research facilities, subject to the provisions of this section.

**(2) Construction and cost of construction**

For purposes of this section, the terms “construction” and “cost of construction” include the construction of new buildings and the expansion, renovation, remodeling, and alteration of existing buildings, including architects’ fees, but do not include the cost of acquisition of land or off-site improvements.

**(b) Scientific and technical review boards for merit-based review of proposals****(1) In general: approval as precondition to grants****(A) Establishment**

There is established a Scientific and Technical Review Board on Biomedical and Behavioral Research Facilities (referred to in this section as the “Board”).

**(B) Requirement**

The Director of NIH, acting through the Office of the Director of NIH, may approve